ROCKVILLE, Md.--(BUSINESS WIRE)--Innovative Biosensors, Inc. (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens for both the biodefense and clinical infectious disease markets, today announced that it has been awarded a contract to provide reagents and technical support for the proprietary CANARY™ technology-based detection and identification system installed and implemented at one of the most important structures in the National Capitol Region.
